Bod Science Ltd (ASX: BOD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Bod Science Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Bod Science Ltd (ASX: BOD)
Latest News
Healthcare Shares
Why a COVID-19 trial is exciting BOD (ASX:BOD) investors today?
Share Gainers
These 3 ASX Healthcare shares are running hot today
Share Market News
Why the Bod (ASX:BDA) share price is climbing today
Cannabis Shares
Up 21%, why the Bod (ASX:BDA) share price is smoking the market today
Share Market News
Bod (ASX:BDA) share price soars on United States market entry
Share Market News
Why the Bod (ASX:BDA) share price is tracking 5% higher today
Share Market News
Why the Bod (ASX:BDA) share price is soaring 11%
Share Gainers
Why Atomos, BOD Australia, Galaxy, & Zebit shares are racing higher
Share Market News
Why the Bod (ASX:BDA) share price is rising 5% today
Share Market News
Why the BOD (ASX:BDA) share price is on the run today
Share Market News
BOD (ASX:BDA) share price soars 8% on product launch
Share Market News
Bod share price surges 5% on record revenue growth
BOD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Bod Science Ltd
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer andmedical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 Aug 2024 | David Baker | Expiry | 937,500 | $22,500 |
Options expired.
|
02 Aug 2024 | Joanne (Jo) Patterson | Cancelled | 413,166 | $9,915 |
As advised by the company. 696,273 LTI Rights
|
02 Aug 2024 | George Livery | Expiry | 1,000,000 | $24,000 |
Options expired.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David Lewis Baker | Non-Executive DirectorNon-Executive Chairman | Apr 2022 |
Mr Baker is a commercial advisor and company director with over 40 years' experience in law, investment banking, public company leadership and corporate governance. He has industry knowledge across a range of sectors and a sophisticated understanding of financial markets. David is also a co-founder of Baker Cook Advisory which is a boutique provider of outsourced legal, commercial and governance advice and mediation services for corporations and government agencies. He is Chair of the Risk Committee.
|
Ms Joanne (Jo) Patterson | Chief Executive OfficerExecutive Director | Oct 2016 |
Ms Patterson has held multiple CEO and Managing Director roles over her career. She has more than 20 years of business experience in Australia and overseas. She has developed a number of businesses from start-up. She has also grown established organisations through mergers and acquisitions. The breadth of her commercial acumen is evidenced by her leadership of companies in the technology, advertising and beauty sectors. Her experiences led her to establish Bod in 2014 and then to subsequently list the business on the ASX in 2016.
|
Mr George Livery | Non-Executive Director | Sep 2018 |
Mr Livery has enjoyed senior executive roles across industries for the last 30 years, domestically and internationally as an expat. A C-level executive for the last 25 years, George's career has included CEO of Village Cinemas Australia, COO of Village International, Commercial Director at Hoyts Ltd, Director of Operations (Non Academic Services) at University of Sydney's USU, Commercial Director at Swisse Vitamins and Director of Strategy & Corporate at Swisse Wellness Group. Most recently George has enjoyed Chairperson, Non-executive Director and CoSec roles on ASX listed and private companies. George also led the corporate integration of Swisse Wellness into the Hong Kong listed H&H Group of companies and enjoyed a dual role during that time as Group Senior VP Legal and Risk. George has held board positions across a number of industries including the NFP sector. He is Member of the Risk Committee.
|
Mr Akash Bedi | Non-Executive Director | Jul 2019 |
Mr Bedi is the Chief Strategy and Operations Officer of Health & Happiness International Holdings Limited from December 2019. He joined the Group in July 2018 as Senior Director of Strategy and Corporate Affairs. As part of his role at the Group, Akash is responsible for overall procurement, logistics, production and supply chain for all H&H Group brands and is also responsible for developing business strategies and roadmaps, identifying growth opportunities and strengthening the Group's industry and market insight capabilities. In the last three years, he has been leading and managing the Swisse business for India and the Middle Eastern market. Akash also leads mergers and acquisitions for the Group and strategic investments for NewH2 Fund (the corporate venture subsidiary of the Group), which focuses on investing in global startups and growth companies with technologies and businesses of strategic importance. Prior to joining H&H, Akash held the position of Director, Global Consumer & Retail at HSBC for over 10 years from May 2008 where he worked on mergers and acquisition transactions from its global offices in New York, London and Hong Kong. Other current directorships: Else Nutrition Holdings, Inc. He is Member of the Risk Committee.
|
Ms Carlie Hodges | Company Secretary | Jan 2023 |
-
|
Adrian Sturrock | Chief Financial Officer |
-
|
|
Craig Weller | Chief Technology Officer |
-
|
|
Carlie Hodges | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 29,061,130 | 16.39% |
Dutch Ink (2010) Pty Ltd | 15,278,286 | 8.61% |
Health And Beauty Enterprise Pty Limited | 6,375,000 | 3.59% |
Baker Cook Advisory <Baker Cook Super A/C> | 6,375,000 | 3.59% |
Noir Ted Pty Ltd | 4,852,329 | 2.74% |
Awj Family Pty Ltd <Aw Johnson Family A/C> | 4,445,346 | 2.51% |
Btt Sciences Ltd | 3,750,000 | 2.11% |
S3 Consortium Pty Ltd | 3,535,112 | 1.99% |
Gp Securities Pty Ltd | 3,500,416 | 1.97% |
Hendo Family Superannuation Pty Ltd <Henderson Superfund A/C> | 2,235,295 | 1.26% |
Avl Nominees Pty Ltd <Avl Holdings A/C> | 2,000,000 | 1.13% |
Biatan Pty Ltd <Mahoney Family A/C> | 1,968,419 | 1.11% |
Jimzbal Pty Ltd <Jimzbal Super A/C> | 1,710,000 | 0.96% |
Toucan Trading Pty Ltd | 1,562,500 | 0.88% |
Lake Pacific Pty Ltd | 1,450,000 | 0.82% |
Mrs Emma Isabell Nixon <Cicerm A/C> | 1,203,209 | 0.68% |
Vagg Family Pty Ltd | 1,165,173 | 0.66% |
Yoix Pty Ltd | 1,010,000 | 0.57% |
Mr Werner Josef Gallautz | 1,000,000 | 0.56% |
Mr Angus William Johnson and Mrs Lindy Johnson <The Denasuper Fund A/C> | 961,084 | 0.54% |